Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting

被引：0
|
作者：
Bu, Qiling [1 ]
Zhu, Hong-Hu [1 ,2 ]
Chen, Wenming [1 ]
机构：
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Hematol, 8 Gongtinanlu, Beijing 100020, Peoples R China
[2] Chinese Inst Med Res, Beijing 100005, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2025年 / 18卷 / 01期
关键词：
Immunoglobulin light chain amyloidosis; Targeted therapies; Clinical trials;
D O I：
10.1186/s13045-025-01681-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
    Zheng, Huijian
    Xian, Huajian
    Zhang, Wenjie
    Lu, Chaoqun
    Pan, Renyao
    Liu, Han
    Xu, Zhenshu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [2] CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting
    Kong, Ran
    Liu, Bingyu
    Wang, Hua
    Lu, Tiange
    Zhou, Xiangxiang
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [3] Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting
    Guangcai Zhong
    Ran Kong
    Shi Feng
    Cong Wang
    Qingbo Hao
    Weilin Xie
    Xiangxiang Zhou
    Journal of Hematology & Oncology, 17
  • [4] Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting
    Zhong, Guangcai
    Kong, Ran
    Feng, Shi
    Wang, Cong
    Hao, Qingbo
    Xie, Weilin
    Zhou, Xiangxiang
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [5] Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
    Yang Cao
    Emanuela C. Marcucci
    Lihua E. Budde
    Journal of Hematology & Oncology, 16
  • [6] Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
    Cao, Yang
    Marcucci, Emanuela C.
    Budde, Lihua E.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [7] HIV associated lymphoma: latest updates from 2023 ASH annual meeting
    Wang, Chaoyu
    Xiao, Qing
    Zhang, Xiaomei
    Liu, Yao
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [8] Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
    DiNardo, Katherine W. W.
    LeBlanc, Thomas W. W.
    Chen, Hui
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [9] Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
    Katherine W. DiNardo
    Thomas W. LeBlanc
    Hui Chen
    Journal of Hematology & Oncology, 16
  • [10] Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting
    Xu, Jieyu
    Zhu, Hong-Hu
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
12345